QT Interval Early Negative Signal Would Lessen Burden In Later Trials
QT interval prolongation may not need to be evaluated "intensively" in late phase trials if preclinical and Phase I studies do not show a positive signal, participants in a Drug Information Association workshop generally agreed
You may also be interested in...
Lundbeck CEO-elect Claus Braestrup will oversee the company's renewed attempt to launch the antipsychotic Serlect (sertindole) in the U.S. when he assumes leadership of the Danish company in November
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011